PCSK9 Inhibitors Cut LDL Cholesterol, CVD Risk

Share this content:
PCSK9 Inhibitors Cut LDL Cholesterol, CVD Risk
PCSK9 Inhibitors Cut LDL Cholesterol, CVD Risk

(HealthDay News) -- A new class of cholesterol medication could sharply cut low-density lipoprotein (LDL) cholesterol in patients who don't fare well on statins, a new research review confirms. The findings were published online April 28 in the Annals of Internal Medicine.

The drugs, known as PCSK9 inhibitors, are not yet on the market. But the U.S. Food and Drug Administration is expected to decide later this year on the first two medications in the class: evolocumab (Repatha) and alirocumab (Praluent). A team of researchers led by Eliano Navarese, M.D., Ph.D., of Heinrich Heine University in Dusseldorf, Germany, pooled the results of 24 clinical trials involving 10,159 patients. Some compared a PCSK9 inhibitor to a placebo, while others used ezetimibe (Zetia) for comparison.

The review of 24 clinical trials found that PCSK9 inhibitors lowered patients' LDL cholesterol by about 47 percent, on average. More importantly, the drugs seemed to cut the risk of myocardial infarction and cardiovascular mortality, according to the researchers.

"The initial clinical trial experience with PCSK9 inhibitors fuels cautious enthusiasm," write the authors of an accompanying editorial. "The meta-analysis by Navarese and colleagues provides important preliminary information on clinical outcomes as the FDA considers approval of PCSK9 inhibitors for clinical use. Confirmation of these findings in long-term, ongoing, pivotal trials with prespecified primary cardiovascular disease end points and monitoring of a broad range of adverse events will help establish the role of these novel agents in cardiovascular disease risk management."

Full Text (subscription or payment may be required)
Editorial

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA OKs Doptelet for Liver Dz Patients Undergoing Procedures

FDA OKs Doptelet for Liver Dz Patients Undergoing ...

Doptelet reduces the need for platelet transfusion or any rescue therapy on day of procedure

Slower Decline in Lung Function With Anthocyanin Intake

Slower Decline in Lung Function With Anthocyanin Intake

Slower annual rates of decline in FEV1 and FVC for those in highest quartile of anthocyanin intake

Bioengineering Feasible for Airway Reconstruction

Bioengineering Feasible for Airway Reconstruction

Bioengineered tracheal and bronchial reconstruction reported using stented aortic matrices

is free, fast, and customized just for you!

Already a member?

Sign In Now »